Get the content you want anytime you want.

Latest News From Contagion® Live

Latest News

Cloudbreak Antiviral Conjugate Demonstrates Potent In Vitro Activity
Cidara Therapeutics has developed CB-012, a stable conjugate of a highly potent antiviral agent linked to human IgG1 Fc, and investigators are evaluating the asset for the treatment and prevention of seasonal and pandemic influenza A and B infections.
ASPECT-NP: Ceftolozane/Tazobactam Efficacious for Ventilated Nosocomial Pneumonia
The ASPECT-NP trial compared a new 3-gram dose regimen of ceftolozane/tazobactam versus meropenem in the treatment of ventilated nosocomial pneumonia.
CAMERA2: Combination Therapy for MRSA Bacteremia Effective but Linked to Higher Mortality, AKI Rates
Investigators found increased mortality in the combination arm where 21% of patients died vs 16% in the standard therapy arm, although the number of patients with persistent bacteremia at day 5 in the combination arm was significantly reduced compared with standard therapy.
Study Demonstrates Proof-of-Concept for Microneedle-Based Antimicrobial Sensing
A UK-based study team conducted an evaluation of real-time penicillin monitoring via minimally invasive, microneedle-based penicillin biosensor.
Evaluating Cloudbreak Molecule for Protection Against <i>Acinetobacter</i> Pneumonia
A study found that the molecule, Compound A, has potent activity against Acinetobacter Pneumonia in mice possibly by a dual killing mechanism and by reducing lipopolysaccharide-induced vascular leak.
Rezafungin Superior to Micafungin to Treat Resistant Intra-abdominal Candidiasis
Rezafungin achieved greater and more prolonged penetration at sites of intra-abdominal candidiasis than micafungin, which correlates with significantly greater activity against FKS-mutant Candida glabrata clinical strains.
Eravacycline Exhibits 'Excellent' In Vitro Activity Against Enterobacteriaceae, Study Reports
A study found that eracavycline was 2-4-fold more active than tigecycline against isolates that produced ESBL and at least 8-fold more active than tigecycline against A baumannii.
With Potent In Vitro Activity, Cefiderocol a Promising Option for Treating Resistance
Investigators detail the activity of cefiderocol, a novel parenteral siderophore cephalosporin, against carbapenem-resistant clinical isolates.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.